COVID-19 associated rhinosinusitis mucormycosis due to Rhizopus arrhizus: A rare but potentially fatal infection occurring after treatment with corticosteroids

Payam Tabarsi  
Shahid Beheshti University of Medical Sciences

Neda Khalili  
Tehran University of Medical Sciences

Mihan Pourabdollah  
Shahid Beheshti University of Medical Sciences

Somayeh Sharifynia  
Shahid Beheshti University of Medical Sciences

Ali Safavi Naelni  
Shahid Beheshti University of Medical Sciences

Jahangir Gorbani  
Shahid Beheshti University of Medical Sciences

Abdolreza Mohamadnia  
Shahid Beheshti University of Medical Sciences

Zahra Abtahian  
Shahid Beheshti University of Medical Sciences

Elham Askari  
(e.askari@sbmu.ac.ir)  
Shahid Beheshti University of Medical Sciences

Case Report

Keywords: coronavirus disease-2019, corticosteroids, fungal, mucormycosis, Rhizopus

DOI: https://doi.org/10.21203/rs.3.rs-398594/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Coronavirus disease 2019 (COVID-19) first emerged in Wuhan, China in December 2019, and since then the frequency of bacterial and fungal coinfections has been continuously rising. While invasive pulmonary aspergillosis is increasingly being recognized in association with COVID-19, there is limited information with regards to COVID-19 associated mucormycosis. Here, we describe a 50-year-old woman with uncontrolled diabetes who received systemic corticosteroids and remdesivir during her admission for COVID-19. Few days after discharge, the patient was readmitted due to facial swelling and numbness, and a diagnosis of COVID-19 associated rhinosinusitis mucormycosis due to *Rhizopus arrhizus* (formerly *Rhizopus oryzae*) was confirmed with sequencing of the internal transcribed spacer (ITS) region of the ribosomal DNA. This report aims to address the importance of short-term follow-up in COVID-19 patients who have received systemic corticosteroids, particularly those with predisposing conditions, as early detection and prompt, aggressive treatment is essential for the management of invasive fungal infections.

Introduction

Emerging evidence suggests that patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may develop bacterial and fungal secondary infections [1]. While invasive pulmonary aspergillosis (IPA) is increasingly being recognized in association with coronavirus disease 2019 (COVID-19), especially in critically ill patients hospitalized in the intensive care unit, [2] there are only a few cases of COVID-19 associated mucormycosis (CAM) available in the literature [3]. Mucormycosis is a rare, opportunistic, highly fatal fungal infection that typically occurs in individuals with underlying compromising conditions, such as diabetes mellitus, corticosteroid use, hematologic malignancies, neutropenia, solid organ/allogeneic stem cell transplant, primary immunodeficiency, and treatment with immunosuppressants. Nevertheless, such infections can be seen in apparently immunocompetent patients on extremely rare occasions [4]. Rhino-orbito-cerebral mucormycosis is considered as the most common manifestation of mucormycosis that is thought to be acquired via the inhalation of fungal spores into the paranasal sinuses. Here, we describe a patient with uncontrolled diabetes who received dexamethasone and remdesivir for COVID-19 treatment, but was readmitted after discharge with a diagnosis of rhinocerebral mucormycosis.

Case Report

A 50-year-old woman presented with a 3-day history of dry cough, shortness of breath, myalgia, and fatigue. Her past medical history was positive for type 2 diabetes mellitus and hypertension, which had been diagnosed five years ago. She had also undergone gastric bypass surgery for weight loss two years before the current admission. The patient did not take any medications for her diabetes as she assumed that she had controlled blood sugars after her surgery and maybe also due to her poor compliance to antidiabetic therapy, but used two antihypertensive drugs (diltiazem and losartan) on a daily basis. She had no history of tobacco smoking or alcohol consumption. The patient was admitted with a presumptive diagnosis of coronavirus disease 2019 (COVID-19). Upon admission, she was hemodynamically stable with a blood pressure of 160/100 mmHg and a pulse rate of 78 bpm. She had no fever (oral temperature = 37.2 °C), but had an increased respiratory rate of 32 breaths/min and an oxygen saturation of 88% on room air. Blood tests revealed normal results and her random plasma glucose level was 224 mg/dl. The patient tested positive for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) and a diagnosis of COVID-19 pneumonia was confirmed. During hospitalization, remdesivir (200 mg on day 1 and 100 mg on days 2-5) and dexamethasone (6 mg once daily for 10 days) were initiated for the patient. After 21 days, the patient was discharged with significant clinical improvement and an oxygen saturation of 95% on room air.

Five days later, the patient was readmitted due to facial swelling, facial numbness, periorbital edema and erythema, which were more prominent on the left side of the face, and headache (Figure 1). A careful and thorough physical examination revealed necrotic eschars on the palate and nasal turbinates. Subsequently, the patient underwent nasal endoscopy for further investigation; surgical evaluation was immediately performed for debridement of the necrotic tissues and multiple biopsies were obtained for diagnostic purposes. At admission, laboratory tests were as follows: random plasma glucose level = 256 mg/dl, hemoglobin A1c = 7.4%, leukocytes = 12.8 × 10^3 /µl (neutrophils = 78%), hemoglobin = 11.4 g/dl, c-reactive protein = 53 mg/l, erythrocyte sedimentation rate = 71 mm/h and lactate dehydrogenase = 402 U/l. All other laboratory tests were within normal limits (Table 1). In addition, paranasal sinuses computed tomography (PNS CT) showed severe mucosal thickening of left maxillary sinus with erosive changes of maxillary sinus wall and the left inferior orbital rim, which was in favor of invasive fungal rhinosinuitis.
Histopathological examination of tissue biopsies, which were necrotic and suppurative, showed broad, pauciseptate hyphae with right-angle branching that were visible within the wall and lumen of blood vessels. Direct smear with 10% KOH revealed hyaline mycelium with hyphae typical of Mucorales. Culture of the tissue on Sabouraud dextrose agar (SDA) at 25 °C and 35 °C yielded a positive result, showing growth of grayish white (and later grayish dark brown) colonies with a woolly texture 2 days after incubation. On lactophenol cotton blue staining of the cultured fungi, hyphae with nodal rhizoids and short sporangiophores with round black sporangia were seen (Figure 2). Finally, sequencing of the internal transcribed spacer (ITS) region of the ribosomal DNA confirmed the diagnosis of infection by *Rhizopus arrhizus* (formerly *Rhizopus oryzae*). Sequencing was performed by amplification using ITS1 and ITS4 primers. Sequences were compared to the National Center for Biotechnology Information Genbank database using the BLAST algorithm (https://blast.ncbi.nlm.nih.gov/Blast.cgi) to confirm the identification of the organism as *R. arrhizus*.

The patient received intravenous liposomal amphotericin B during her stay at hospital and was finally discharged after 28 days.

**Discussion**

With more than one year since the emergence of COVID-19 in China, there is still lack of a definitive and specific treatment against SARS-CoV-2. Several therapeutic agents have been investigated for the management of critically ill patients with COVID-19, such as corticosteroids, antiviral and immunomodulatory drugs; none have been clinically efficacious though [5, 6].

Administration of systemic corticosteroids has been shown to decrease mortality in particular subgroups of patients with COVID-19, with the greatest efficacy shown in patients receiving invasive mechanical ventilation [7, 8]. Nevertheless, treatment with systemic corticosteroids causes immunosuppression, thereby predisposing patients to invasive fungal rhinosinusitis. Corticosteroids may induce hyperglycemia, leading to activation of immune cells, secretion of proinflammatory cytokines and development of inflammation. According to the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) consensus, prolonged use of corticosteroids at a therapeutic dose of ≥ 0.3 mg/kg for at least three weeks in the past 60 days is considered a risk factor for invasive fungal diseases [9]. In a study by Jeong et al., corticosteroid use was identified as a predisposing factor in about 33% (273/851) of patients with mucormycosis. Also, COVID-19 patients with diabetes are not only at increased risk of developing severe disease, but are also more prone to invasive fungal infections [10]. Diabetes mellitus can alter the body's immunological response to pathogens by enhancing fungal proliferation and diminishing the phagocytic capacity of host immune cells [11]. In addition, the ketone reductase enzyme in Mucorales including *Rhizopus* organisms allows them to thrive in high glucose, acidic conditions. This is the reason for the stimulated growth of these organisms in patients with diabetic ketoacidosis [12]. The case presented here, however, did not have diabetic ketoacidosis. Furthermore, IL-6-inhibiting drugs such as tocilizumab may cause immune dysregulation and increase the risk of secondary infections without providing substantial clinical benefit in patients with COVID-19 [13, 14]. COVID-19 patients with acute respiratory distress might be susceptible to secondary infections as a result of immune dysregulation [15]. Patients infected with SARS-CoV-2 have declined levels of circulating lymphocytes and T cell subsets, resulting in suboptimal cell-mediated immune responses [16]. With these in mind, one can anticipate that critically ill patients with COVID-19 are at increased risk of developing severe invasive fungal infections.

Acute invasive fungal rhinosinusitis is characterized by thrombosis, infarction and necrosis of involved tissues due to vascular invasion by the fungus, which manifests as black palatal or gingival eschars and/or perforation of the nasal septum. Rhinocerebral mucormycosis usually presents with an acute onset of fever, facial pain, nasal congestion, headache, perinasal swelling, facial numbness, and visual changes such as diplopia and proptosis. Facial numbness, as seen in the present case, is caused by fifth cranial nerve involvement, which indicates that the infection has spread beyond the sinuses. With the rapid spread of the fungal infection to the brain, obtundation, cranial nerve palsy, cavernous sinus thrombosis, and carotid artery involvement may occur. Cavernous sinus thrombosis is a complication that is usually seen when the fungal infection enters through direct wound contamination into the oral cavity, thereby involving the mandible. On the other hand, palatal ulcers are commonly seen in infections originating from the nose and PNS [11].

The estimated incidence of mucormycosis varies among different continents and/or countries; in 2019, the incidence of mucormycosis (per million) was reported as follows: Europe (from 0.2 cases in Denmark to 95 cases in Portugal), USA (3.0 cases), Canada (1.2 cases), Australia (0.6 cases), and India (140 cases). However, the incidence of mucormycosis in patients on dexamethasone without DKA has not been reported in the literature so far.
Based on the available literature, six studies corresponding to 11 patients, including ours, have reported rhino-orbito-cerebral mucormycosis in association with COVID-19. Detailed descriptions of these cases are provided in Table 2. Based on these studies, all patients had diabetes, either previously diagnosed or detected during COVID-19 admission; however, not all patients had received corticosteroids before initiation of symptoms related to mucormycosis. Importantly, the causative fungus has only been identified in a few studies. So, the most common species causing invasive rhinocerebral mucormycosis could not be determined among these patients. It is worthy to note that while few patients developed symptoms during hospital stay, others, such as our case, developed symptoms after being discharged from the hospital for COVID-19 treatment. Therefore, it is very important to make all physicians aware of the fact that invasive fungal infections might occur after patients with COVID-19 have been discharged and so, patients, particularly those with predisposing conditions, should be informed about the red flag symptoms of invasive mucormycosis.

Mucormycosis has been diagnosed postmortem in two patients with COVID-19 [17, 18]; hence, it is rational to assume that a fatal outcome may possibly be precipitated by invasive fungal infections such as mucormycosis in a number of COVID-19 patients with predisposing factors, and that this devastating infection might have been underdiagnosed during the pandemic. Therefore, the early diagnosis of invasive fungal infections, such as rhino-orbito-cerebral mucormycosis, is of critical importance in COVID-19 patients with sinus complaints, particularly those with underlying diseases and those who have received systemic corticosteroids, since prompt, aggressive treatment is essential for an optimal outcome. Indeed, early diagnosis and timely management with surgical debridement plus amphotericin B most probably contributed to the favorable outcome achieved in the patient presented here. However, in four previously reported case reports of rhino-orbito-cerebral mucormycosis associated with COVID-19, patients died despite receiving therapy [19-22].

In conclusion, defining the characteristics of patients with invasive mucormycosis associated with COVID-19 may help to better evaluate the course of fungal infection in patients with COVID-19 and to determine the most appropriate and applicable preventive measures in highly susceptible COVID-19 patients with the intention to reduce morbidity and mortality. In addition, it is important to note that corticosteroids may be associated with potentially fatal side effects in COVID-19 patients, acting as a double-edged sword.

Declarations

Author contributions:
Payam Tabarsi, Neda Khalili, and Elham Askari were responsible for study conception and design; Payam Tabarsi, Elham Askari, Mihan Pourabdollah, Somayeh Sharifnymia, Ali Safavi Naeini, Jahangir Ghorbani, Abdolreza Mohamadnia, and Zahra Abtahian were responsible for acquisition of data and patient management; Neda Khalili and Elham Askari were responsible for drafting and revision of the manuscript. All authors have read and approved the final version of the manuscript.

Acknowledgments: None

Disclosures

Conflict(s) of interest: The authors declare that they have no conflict of interest.

Financial support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical conduct of research statement: This study was approved by the ethics committee of our institution. All procedures followed the ethical standards of the 1975 Declaration of Helsinki, and as revised in 2000. Informed consent to participate in the study was obtained from the participant. The participant has consented to the submission of the case report to the journal.

References

1. Clancy CJ, Schwartz IS, Kula B, Nguyen MH. Bacterial superinfections among persons with coronavirus disease 2019: A comprehensive review of data from postmortem studies. *Open Forum Infectious Diseases* 8(3), ofab065 (2021).
2. Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. *The Lancet Respiratory Medicine* 8(6), e48-e49 (2020).
Garg D, Muthu V, Sehgal IS et al. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia doi:10.1007/s11046-021-00528-2 (2021).

Xia ZK, Wang WL, Yang RY. Slowly progressive cutaneous, rhinofacial, and pulmonary mucormycosis caused by Mucor irregularis in an immunocompetent woman. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 56(7), 993-995 (2013).

* This study described a very rare case of mucormycosis in an immunocompetent woman.

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). Statpearls [internet] (2020).

Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 383(19), 1813-1826 (2020).

** This study investigated the association between IL-6 inhibition and secondary infections in COVID-19 patients.

Afroze SN, Korlepara R, Rao GV, Madala J. Mucormycosis in a Diabetic Patient: A Case Report with an Insight into Its Pathophysiology. Contemp Clin Dent 8(4), 662-666 (2017).

** This study discussed the secondary infections and superinfections associated with COVID-19.

Chen G, Wu D, Guo W et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of clinical investigation 130(5), 2620-2629 (2020).

** An insightful study about the effects of COVID-19 on the immune system.

Monte Junior ESD, Santos MELD, Ribeiro IB et al. Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report. Clin Endosc 53(6), 746-749 (2020).

Hanley B, Naresh KN, Roufosse C et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. The Lancet Microbe 1(6), e245-e253 (2020).

Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus 12(9), e10726 (2020).

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. The American Journal of Emergency Medicine 42(264), e5-e8 (2020).
21. Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19. *Cureus* 13(2), e13163 (2021).

22. Mekonnen ZK, Ashraf DC, Jankowski T *et al.* Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome. *Ophthalmic Plastic & Reconstructive Surgery* 37(2), e40-e80 (2021).

23. Sen M, Lahane S, Lahane T, Parekh R, Honavar S. Mucor in a Viral Land: A Tale of Two Pathogens. *Indian Journal of Ophthalmology* 69(2), 244-252 (2021).

### Tables

#### Table 1. Laboratory tests of the patient in the second admission

| Blood routine          |       |
|------------------------|-------|
| White blood cell, × 10³/µl | 12.8  |
| Neutrophil (%)         | 78    |
| Lymphocyte (%)         | 18    |
| Hemoglobin, g/dl       | 11.4  |
| Platelet, × 10³/µl     | 152   |

| Blood chemistry        |       |
|------------------------|-------|
| Urea, mg/dl            | 23    |
| Creatinine, mg/dl      | 0.6   |
| Lactate dehydrogenase, U/l | 402  |
| Aspartate aminotransferase, U/l | 25    |
| Alanine aminotransferase, U/l | 13    |
| Blood sugar, mg/dl     | 256   |
| Hemoglobin A1c, %      | 7.4   |

| Arterial blood gas     |       |
|------------------------|-------|
| PH                     | 7.36  |
| PCO₂                   | 44    |
| HCO₃                   | 23    |

| Infection-related markers |       |
|---------------------------|-------|
| Erythrocyte sedimentation rate, mm/h | 71    |
| Ferritin, ng/ml           | 672   |
| C-reactive protein, mg/l  | 53    |

#### Table 2. Description of previously reported cases of rhino-orbito-cerebral mucormycosis in patients with COVID-19
| Outcome                          | Died | Alive (All had vision loss) | Died | Died | Died |
|---------------------------------|------|----------------------------|------|------|------|
| **Causative fungus**            | Not identified | Not identified | Not identified | Lichtheimia spp | Rhizopus spp |
| **Diagnosis**                   | Culture | Histopathology | Culture | Culture | NA |
| **Initiation of symptoms †**    | Day 10 | Day 0 | Day 17 ‡ | Day 30 ‡ | Day 0 |
| **Risk factors**                | Diabetes + ARDS + methylprednisolone + dexamethasone + tocilizumab | Diabetes + methylprednisolone + prednisolone | Diabetes + prednisolone + dexamethasone | Diabetes + prednisolone | Diabetes + dexamethasone |
| **Patient characteristics**    | 60-year-old male with bilateral lid edema | Patient 1: 46-year-old male with ptosis, periorcular swelling and loss of vision | Patient 2: 60-year-old male with ptosis, painful and limited eye movements | 33-year-old female with altered mental status, ptosis, proptosis, fixed pupil and ophthalmoplegia | 24-year-old female with left midface pain, left eyelid swelling, proptosis and conjunctival chemosis | 60-year-old male with right-sided proptosis, eyelid swelling and conjunctival chemosis |
| Study          | Patient 3: 73-year-old male with ptosis, painful and limited eye movements | maxillary hypoesthesia |
|----------------|----------------------------------------------------------------------------|------------------------|
|                | Patient 4: 72-year-old male with periocular swelling, fixed pupil and loss of vision |
|                | Patient 5: 62-year-old male with ptosis, fixed pupil and loss of vision |
|                | Patient 6: 47-year-old male with ptosis, periocular swelling and loss of vision |

| Study          | Mehta et al. [19] | Sen et al. [23] | Werthman-Ehrenreich et al. [20] | Waizel-Haiat et al. [21] | Mekonnen et al. [22] |

† Date of admission for COVID-19 is considered as baseline (Day 0).

‡ These patients developed symptoms suggestive of mucormycosis after discharge.